Evaluation of lipid parameters and family history of diabetes mellitus in polycystic ovary syndrome

Yıl 2013, Cilt: 40 Sayı: 3, 414 - 417, 01.09.2013

İlay Gözükara Eda Ülkü Uludağ Suna Kabil Kucur Havva Yılmaz Ayşe Çarlıoğlu

https://doi.org/10.5798/diclemedj.0921.2013.03.0300

Öz

Objective: In the present study we investigated lipid parameters of Polycystic Ovary Syndrome (PCOS) patients and Diabetes Mellitus (DM) history of their family and relatives. Methods: In this cross-sectional study, one hundred and twenty patients with PCOS and 30 healthy controls were involved at Erzurum Research and Training Hospital. History, Body mass index (BMI), ultrasonography findings, blood hormone profiles (Follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), thyroid-stimulating hormone (TSH), total and free testosterone (Total-T and Free-T), prolactin (PRL)), and serum lipids (total cholesterol (Total-C), high-density cholesterol (HDL-C), low-density cholesterol (LDL-C), and triglycerides (TG), fasting blood glucose and plasma insulin level were measured. HOMA-IR (Homeostatic model assessment-insulin resistance) was calculated. Results: DM history in the family was found in 29 (24%) of PCOS patients and 2 (6%) of healthy controls. The difference between groups was statistically significant (p

Anahtar Kelimeler

PCOS, Family history, DM, lipid parameters

Polikistik over sendromlu hastalarda lipid parametrelerinin ve ailede diabetes mellitus sıklığının değerlendirilmesi

Öz

Amaç: Bu çalışmada polikistik over sendromu (PKOS) tanısı alan hastalarda lipid parametreleri ile hastaların aile ve akrabalarında Diabetes Mellitus (DM) sıklığı araştırılmıştır. Yöntemler: Kesitsel yapılan bu çalışmada Erzurum Bölge Eğitim ve Araştırma Hastanesinde PKOS tanısı almış 120 hasta ve 30 sağlıklı kontrol grubu çalışmaya dahil edilmiştir. Hastaların vücut kitle indeksleri, soy geçmişleri, ultrasonografik bulguları, kan hormon profilleri (Folikül stimulan hormon (FSH), Luteinizan hormon (LH), total ve serbest testesteron, prolaktin (PRL), Tiroid stimulan hormon (TSH)), lipid parametreleri (düşük dansiteli lipoprotein (LDL), yüksek dansiteli lipoprotein (HDL), trigliserid), plazma insülin seviyeleri, açlık kan glukoz değeri ve HOMA-IR (Homeostatic model assessment -insulin resistance) kaydedildi. Hastaların ailesinde ve akrabalarında DM olup olmadığı sorgulandı. Bulgular: Ailede DM hikayesi PKOS\'lu hastaların 29 (%24)\' unda, kontrol grubu hastalarının 2 (%6)\' sinde saptanmıştır. Uzak akrabalarda DM hikayesi PKOS\'lu grupta 45 (%35) hastada, kontrol grubunda ise 5 (%17) hastada saptandı. HOMA-IR değerleri, açlık kan şekeri ve insülin seviyeleri PKOS grubunda istatistiksel olarak anlamlı yüksek bulundu (p0,05). Sonuç: PKOS lu hastaların aile ve akrabalarında DM sıklığının kontrol grubuna göre istatistiksel olarak anlamlı şekilde daha fazla olduğu saptandı. Önceki çalışmaların aksine olarak bu çalışmada polikistik over sendromunda lipid parametrelerinde bozulma saptanmadı.

Anahtar Kelimeler

PKOS, aile hikayesi, DM, lipid parametreleri

Kaynakça

• March WA, Moore VM, Willson KJ, et al. The prevalence of polycystic ovary syndrome in a community sample as- sessed under contrasting diagnostic criteria. Hum Reprod 2010;2:544-551.
• Evian Annual Reproduction (EVAR) Workshop Group 2010, Fauser BC, Diedrich K, Bouchard P, et al. Contemporary genetic technologies and female reproduction. Hum Reprod Update 2011;17:829-847.
• Legro RS, Strauss JF. Molecular progress in infertility: poly- cystic ovary syndrome. Fertil Steril 2002;78:569-576.
• Hoffman LK, Ehrmann DA. Cardiometabolic features of poly- cystic ovary syndrome. Nat Clin Pract Endocrinol Metab 2008;4: 215-222.
• Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and im- paired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-169.
• Azziz R, Woods KS, Reyna R, et al. The prevalence and fea- tures of the polycystic ovary syndrome in an unselected popu- lation. J Clin Endocrinol Metab 2004;89:2745-2749.
• Radosh L. Drug treatments for polycystic ovary syndrome. Am Fam Physician 2009;79:671-676.
• Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Im- perial J. Prevalence of impaired glucose tolerance and diabe- tes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141-146.
• Gambineri A, Pelusi C, Manicardi E, et al. Glucose intolerance in a large cohort of Mediterranean women with polycystic ovary syndrome phenotype and associated factors. Diabetes 2004;53:2353-2358.
• The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. “Revised 2003 consensus on diagnostic cri- teria and long-term health risks related to polycystic ovary syndrome (PCOS)”. Human Reproduction 2004;19:41–47.
• Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: Insulin resistance and beta- cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-219.
• Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metabol 2005;90:1929-1935.
• El-Mazny A, Abou-Salem N, El-Sherbiny W, El-Mazny A. Insulin resistance, dyslipidemia, and metabolic syndrome in women with polycystic ovary syndrome. Int J Gynaecol Ob- stet 2010;109:239-241.
• Atiomo WU, El-Mahdi E, Hardiman P. Familial associa- tions in women with policyctic ovary syndrome. Fertil Steril 2003;80:143-145.
• Yıldız BO, Yaralı H, Oğuz H, Bayraktar M. Glucose intoler- ance, insulin resistance, and hyperandrogenemia in first de- gree relatives of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:2031-2036.
• Benítez R, Sir-Petermann T, Palomino A, et al. Prevalence of metabolic disorders among family members of patients with polycystic ovary syndrome. Rev Med Chil 2001;129:707- 712.
• Pehlivanoğlu V, Koç Bebek A, Akalın A, Süer N. Polikistik Over Sendromlu Hastaların Reprodüktif Çağdaki Anne ve Kız Kardeşlerinde Metabolik Parametrelerin Değerlendirilmesi. Turkiye Klinikleri J Gynecol Obst 2011;21:148-54.
• Yılmaz M, Bukan N, Ersoy R, et al. Glucose intolerance, in- sulin resistance and cardiovascular risk factors in first degree relatives of women with polycystic ovary syndrome. Hum Reprod 2005;20:2414-2415.
• Sir-Peterman T, Angel B, Maliqueu M, Carvajal F. Prevalance of T2DM and insulin resistance in parents of women with polycystic ovary syndrome. Diabetelogia 2004;45:959-964.
• Crosignani PG, Nicolosi AE. Polycystic ovarian disease: heri- tability and heterogeneity. Hum Reprod Update 2001;7:3-7.
• Freeman R, Pollack R, Rosenbloom E. Assessing impaired glucose tolerance and insulin resistance in polycystic ovar- ian syndrome with a muffin test: an alternative to the glucose tolerance test. Endocrine Practice 2010;16:810-817.
• Farrell K, Antoni MH. Insulin resistance, obesity, inflam- mation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions. Fertil Steril 2010;94:1565-1574.
• Turan V, Erdoğan M, Yeniel Ö, ve ark. Polikistik over send- romu tanısı konmuş 89 hastanın biyokimyasal, hormonal kan parametrelerinin ve klinik bulgularının incelenmesi. Ege Tıp Dergisi 2011;50:179-182.
• Valkenburg O, Steegers-Theunissen RP, Smedts HP, et al. more atherogenic serum lipoprotein profile is present in wom- en with polycystic ovary syndrome: a case-control study. J Clin Endocrinol Metab 2008;93:470-476.